Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya Aids Vaccine Initiative (KAVI), Kenya

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Omosa Manyonyi, Gloria S ^a   Jaoko, Walter ^a   Anzala, Omu ^a   Ogutu, Hilda ^a   Wakasiaka, Sabina ^a   Malogo, Roselyn ^a   Nyange, Jacqueline ^a   Njuguna, Pamela ^a   Ndinya Achola, Jeckoniah ^a   Bhatt, Kirana ^a   Farah, Bashir ^a   Oyaro, Micah ^a   Schmidt, Claudia ^b   Priddy, Frances ^b   Fast, Patricia ^b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE REGISTRY; EOSINOPHILIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; KENYA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NEUTROPENIA; PATIENT SELECTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; REFERENCE VALUE; CLINICAL TRIAL; DIAGNOSIS, MEASUREMENT AND ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STANDARD;

AIDS VACCINES; HUMANS; KENYA; LABORATORY TECHNIQUES AND PROCEDURES; PATIENT SELECTION; REFERENCE STANDARDS;

EID: 79251646493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014580     Document Type: Article

References (15)

1. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, et al. (2010) Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE 5: e12873.
2. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, et al. (2007) Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25: 2120-2127.
3. UNAIDS (2010) Report on the global HIV/AIDS epidemic. Geneva.
4. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, et al. (2008) Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26: 2788-2795.
5. Omosa G, Jaoko W, Wakasiaka S, Ogutu H, Bwayo J (2002) Volunteer Recruitment for phase 1 HIV Vaccine Trials in Nairobi. Baltimore, Maryland, USA: 5th Annual Conference on Vaccine Research.
6. Omosa-Manyonyi G, Jaoko W, Wakasiaka S, Bwayo J, Ndinya-Achola J, et al. (2005) Challenges experienced by the clinical team during the conduct of HIV vaccine clinical trials in Kenya. Montreal, CANADA: AIDS Vaccine 2005.
7. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB (2004) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 351: 1548-1563.
8. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, et al. (2009) CLSIderived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS ONE 4: e4401.
9. Stevens W, Kamali A, Karita E, Anzala O, Sanders EJ, et al. (2008) Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS ONE 3: e2043.
10. Kasili EG, Cardwell CL, Taylor JR (1969) Leucocyte counts on blood donors in Nairobi. East Afr Med J 46: 676-679.
11. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, et al. (2004) Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol 11: 29-34.
12. Ezeilo GC (1972) Non-genetic neutropenia in Africans. Lancet 2: 1003-1004.
13. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, et al. (1999) Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol 6: 410-414.
14. Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, et al. (2003) Immunohematological reference ranges for adults from the Central African Republic. Clin Diagn Lab Immunol 10: 443-445.
15. Shaper AG, Lewis P (1971) Genetic neutropenia in people of African origin. Lancet 2: 1021-1023.